Back to touchmedicalmedia.com

Delivering medical education for a global audience delivered by expert faculty.

touchIME
Read Time: 2 mins

New partnership with National Organization for Rare Disorders (NORD)

Published Online: February 24th 2022
Article:

Touch Medical Media are delighted to announce a new partnership with National Organization for Rare Disorders (NORD)

NORD, is a patient advocacy organization dedicated to individuals with rare diseases and the organizations that serve them. NORD, along with more than 300 patient organization members, is committed to the identification, treatment, and cure of rare disorders through programs of education, advocacy, research, and patient services.

For more than 30 years, NORD has been providing services for patients and their families, rare disease patient organizations, medical professionals, and those seeking to develop new diagnostics and treatments. NORD are here to support every member of the rare disease community with services focused on one ultimate goal: to improve the lives of individuals and families affected by rare diseases. https://rarediseases.org/

NORD represents the USA for both Rare Diseases International (RDI) and Rare Disease Day steering committees and Touch Medical Media are thrilled to help support the Rare Disease Day 2022 – see Awareness Day news here
Please take a look at some of the rare disease content we have across our sites:
touchCARDIO

Wolfgang Linke, ESC 2021 – Key Pathomechanisms of TTNtv-dilated Cardiomyopathy

touchENDOCRINOLOGY

Current medical therapies available for craniopharyngiomas

Ferdy van Geest, ETA 2021: Efficacy of T3 analogue Triac for MCT8 deficiency

touchIMMUNOLOGY

Dr Emanuel Della Torre on novel therapeutic approaches

Bob Geng, AAAAI 2021: Immunoglobulin Replacement Therapy

touchINFECTIOUS DISEASES

Listen to this interview with Prof. Tomas Jelinek on the unmet needs, prevention and treatment of Chikungunya virus

touchNEUROLOGY

Bernd Schwahn – First-in-class treatment approach on Molybdenum cofactor deficiency (MoCD)

Renato Mantegazza – challenges that arise in treating myasthenia gravis

touchONCOLOGY

Bruton’s Tyrosine Kinase Inhibitors for the Treatment of Waldenström’s Macroglobulinaemia: A Canadian Perspective

Pegcetacoplan in Paroxysmal Nocturnal Haemoglobinuria

touchOPHTHALMOLOGY

Paediatric Vernal Keratoconjunctivitis – The VEKTIS Study

touchRESPIRATORY

Watch a short interview with Dr Vincent Cottin on challenges and latest research in IPF

Recent Advances in Primary Ciliary Dyskinesia: From Diagnosis to Treatment

 

Contact us to find out more or to hear about our medical society partnerships.
Share this Article
Related Content In touchIME
Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72